Get started
Author

Judy Murray

E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
2015 · Roisín M. Connolly, Fengmin Zhao, et al. · Journal of Clinical Oncology · 11
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
2025 · Susan C. Scott, Anna Farago, et al. · Cancer Chemotherapy and Pharmacology · 5
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.
2024 · Thatcher Ross Heumann, Mark Yarchoan, et al. · Journal of Clinical Oncology · 5
Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
2015 · Roisin M Connolly, Fengmin Zhao, et al. · Cancer Research · 5
MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.
2026 · Rashmi Bhakuni, Evan Thomas Hall, et al. · Journal of Clinical Oncology · 3
The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma.
2025 · Rashmi Bhakuni, Evan Thomas Hall, et al. · Journal of Clinical Oncology · 3
ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.
2023 · Thatcher Ross Heumann, Mark Yarchoan, et al. · Journal of Clinical Oncology · 3
PDF
A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy–naïve recurrent and/or metastatic androgen receptor (AR)–positive salivary gland cancer (ETCTN 10553).
2026 · Alan Loh Ho, Varinder Kaur, et al. · Journal of Clinical Oncology · 2
Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab
2025 · Evanthia Roussos Torres, Ludmila Danilova, et al. · Research Square · 2
PDF
ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma.
2024 · S. Lindsey Davis, Anup Kasi, et al. · Journal of Clinical Oncology · 1
PDF
Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with the combination of entinostat, nivolumab, and ipilimumab
2026 · Ludmila Danilova, Joseph A. Tandurella, et al. · Communications Medicine
PDF
599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma
2025 · Rashmi Bhakuni, Evan T Hall, et al. · Regular and Young Investigator Award Abstracts
PDF
Works count: 12
Citation count: 40
H-index: 4
I10-index: 1
Year
Topic
Type